ClinicalTrials.gg
RecruitingNCT06332521BABYCRY_1000Updated May 28, 2025

Infant Crying, a Bioacoustic Prognostic Signal for Neurodevelopment

An observational study in Newborn; Vitality, Premature Infants and Infant Development, sponsored by Centre Hospitalier Universitaire de Saint Etienne. Recruiting at 1 site in France. Open to participants aged Up to 4 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-28.

Sponsored by Centre Hospitalier Universitaire de Saint Etienne · Observational

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,100
Ages
Up to 4 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Premature Birth by Centre Hospitalier Universitaire de Saint Etienne — 1 open to participants now, 1 under way, none of them phase 3. Premature Birth · Centre Hospitalier Universitaire de Saint Etienne.

Planned enrollment
Largest of 10
1,100 · median 40
Started
2024
the only one that year
Observational
10 of 11
1 open now
Registered
11th of 11
by date

Among the 11 studies in Premature Birth by Centre Hospitalier Universitaire de Saint Etienne, this one has the largest planned enrollment of the 10 observational ones that give a count, is the only one that started in 2024, is one of 10 observational ones, and was the 11th registered.

Premature Birth

2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.

Browse Premature Birth studies →

Open to participants now

1 of the 11 studies in Premature Birth by Centre Hospitalier Universitaire de Saint Etienne is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.

This study: Up to 4 Days · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Premature Birth by Centre Hospitalier Universitaire de Saint Etienne, or all of them as a file.
02

Study summary

Crying is a vital communication signal for the baby. Product of a complex physiological process, it reflects not only the organization and functioning of the cortical central nervous system and the function of sympathetic and parasympathetic autonomic regulation but also the integrity of three entities: the lungs responsible for ventilatory mechanics and respiratory rhythm, the larynx and its vocal cords as a phonatory organ, and the oropharyngeal tract guaranteeing the resonance of the sound emitted by the vocal cords.

Crying is usually caused by pain, discomfort, hunger, or separation from parents or other caregivers. Crying carries essential information from birth, the expression of which depends closely on the neuroanatomical and functional brain integrity of the child. On a bioacoustic level, crying consists of sequences of complex acoustic signals produced by the vocal folds and filtered by the vocal tract. The vibration frequency of the vocal cords determines the cry's fundamental frequency f0 (and the harmonic frequencies), which is responsible for its more or less low or high pitch. Other acoustic cues also characterize each baby's cry.

Read the detailed description

The objective of the Baby's cry 1000/100 study is to evaluate the acoustic characteristics of crying at birth, of term and premature babies and to correlate them with neurodevelopmental outcomes at 2 years of age to see if the bioacoustic characteristics of crying at birth could be predictive of the baby's neurofunctional integrity.

To achieve this objective, the investigators wish to document a large bank of recordings of the crying of term or premature babies by relying on deep learning and artificial intelligence approaches, making it possible to process large databases quickly, evaluate the links between acoustics of crying and clinical data at the birth of full-term babies who will benefit from systematic neurodevelopmental monitoring at 2 years (Bayley scale).

03

Conditions studied

  • Newborn; Vitality
  • Premature Infants
  • Infant Development

Keywords

  • Newborn
  • Crying
04

Who can participate

Ages eligible
Up to 4 Days
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Full-term baby > 37 weeks Premature baby \< 37 weeks

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For a full-term baby > 37 weeks
  • For a premature baby \< 37 weeks
  • Born in the maternity ward of the Saint-Etienne University Hospital
  • Holder of parental authority having received informed information about the study and their right to object
  • Holder of parental authority affiliated to or beneficiary of a social security system
  • Eutrophic between the 10th and 90th percentile on the neonatal curves)

Exclusion criteria

Exclusion Criteria:

  • Refusal of participation by the holder of parental authority
  • Antenatal pathology, nor perinatal asphyxia
  • Holder of minor parental authority
  • Holder of parental authority under curatorship or guardianship
  • Abnormal T1 audiological screening test.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,100 participants (estimated)
Patient registry
No

Groups and cohorts

  • birth of term babies

    Study of crying in a group of newborns (birth of term babies)

    Other: Acoustic signal analysis method

  • Premature babies

    Study of crying in a group of newborns (Premature babies )

    Other: Acoustic signal analysis method

Interventions

  • OtherAcoustic signal analysis method

    Evaluate at birth in 2 characterized populations of babies born at term or prematurely, the correlation between bioacoustic characteristic of a cry specific to each baby, with the neurodevelopmental data at 2 years.

06

What researchers measure

Primary outcomes

  1. Fundamental frequency f0 (Hz)

    Fundamental frequency f0 (Hz) defined from a crying sequence, the most characteristic elementary index of their individual bioacoustic signature.

    Time frame: At inclusion

  2. Bailey-4 quantitative scale

    neurodevelopment at age 2 measured by the Bailey-4 quantitative scale. The final score is from 40 (Very weak neurodevelopment) to 160 (Very good neurodevelopment)

    Time frame: At 2 years

Secondary outcomes

  1. Percentage voiced frames

    Other bioacoustic characteristics measurable in each bioacoustic sequence

    Time frame: At inclusion

  2. Harmonics of f0 (Hz)

    Other bioacoustic characteristics measurable in each bioacoustic sequence : vibration frequency of the vocal cords, defining a +/- low or high tone

    Time frame: At inclusion

  3. Median pitch f0 (Hz)

    Other bioacoustic characteristics measurable in each bioacoustic sequence

    Time frame: At inclusion

  4. Harmonicity (dB)

    Other bioacoustic characteristics measurable in each bioacoustic sequence

    Time frame: At inclusion

  5. Jitter (Percentage),

    Other bioacoustic characteristics measurable in each bioacoustic sequence

    Time frame: At inclusion

  6. Q25 (Percentage)

    Other bioacoustic characteristics measurable in each bioacoustic sequence : rapid amplitude fluctuations occurring at frequencies between 30 and 150 Hz

    Time frame: At inclusion

  7. Median Cepstral Peak Prominence (CPP) (dB)

    The CPP makes it possible to quantify the "quality" of the voice and the acoustic signal and its degree of harmonicity as opposed to the severity of the dysphonia

    Time frame: At inclusion

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Mar 2028, 47 months after the start.

Of 373 non-industry observational studies under Premature Birth, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 63. This study's planned 47 months is above that.

Counting every sponsor, half of 388 studies reached it within 35 months; a quarter within 19 and three quarters within 61.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2024
First posted
Mar 27, 2024
StartActual
Mar 20, 2024
Primary completionEst.
Mar 1, 2028
CompletionEst.
Mar 1, 2028
Last update
May 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06332521
Responsible party
Sponsor
First posted
Mar 27, 2024
Start date
Mar 20, 2024
Primary completion
Mar 1, 2028 (estimated)
Completion
Mar 1, 2028 (estimated)
Last update
May 28, 2025

Study contacts

HUGUES PATURAL, MD-PhD
Contact
hugues.patural@chu-st-etienne.fr
(0)4 77 82 85 42 ext. +33
HUGUES PATURAL, MD-PhD
principal investigator · CHU DE SAINT-ETIENNE
Nicolas MATHEVON, PhD
study chair · Saint-Etienne University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion